{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:10:36Z","timestamp":1791112236424,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T00:00:00Z","timestamp":1097539200000},"content-version":"vor","delay-in-days":3268,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1995,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dyskinesias occur in the majority of patients with Parkinson's disease chronically treated with <jats:sc>L<\/jats:sc>\u2010DOPA and also occur in several nonhuman primate species after 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP) and <jats:sc>L<\/jats:sc>\u2010DOPA treatment. The common marmoset (<jats:italic>Callithrix jacchus<\/jats:italic>) shows parkinsonian motor deficits after MPTP administration, and we now report dyskinesias occurring in this species during chronic <jats:sc>L<\/jats:sc>\u2010DOPA exposure. Marmosets rendered chronically parkinsonian after MPTP administration were treated orally with <jats:sc>L<\/jats:sc>\u2010DOPA plus carbidopa for 3 weeks. After several days the animals began to display chorea, choreoathetosis, and dystonia. The severity of dyskinesias varied between the animals, with the most severely parkinsonian animals displaying the most dyskinetic movements. Each animal showed an idiosyncratic pattern of dyskinesias, which was highly reproducible. These <jats:sc>L<\/jats:sc>\u2010DOPA\u2010primed animals also received other D<jats:sub>2<\/jats:sub>, D<jats:sub>1<\/jats:sub>, and agonist drugs. Quinpirole, bromocriptine, pergolide, apomorphine, and A\u201077636 all produced dyskinesias that were identical in character to those seen after <jats:sc>L<\/jats:sc>\u2010DOPA administration, but the D<jats:sub>1<\/jats:sub> agonist A\u201077636 gradually abolished dyskinesias while preserving its antiparkinsonian activity. The MPTP\u2010treated marmoset provides a useful model in which to study dyskinesias in Parkinson's disease and to examine new therapeutic strategies aimed at alleviating this common side effect of chronic dopamine replacement therapy.<\/jats:p>","DOI":"10.1002\/mds.870100606","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T09:43:35Z","timestamp":1104486215000},"page":"731-740","source":"Crossref","is-referenced-by-count":196,"title":["Chronic <scp>L<\/scp>\u2010DOPA administration induces dyskinesias in the 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010treated common marmoset (<i>Callithrix jacchus<\/i>)"],"prefix":"10.1002","volume":"10","author":[{"given":"R. K. B.","family":"Pearce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. D.","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.340"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870020201"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.7.949"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(87)90322-8"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1017\/S0317167100037859","article-title":"MPTP\u2010induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms","author":"Crossman AR","year":"1987","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90750-9"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245739"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0022-3565(25)20396-2","article-title":"Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L\u2010DOPA in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010treated monkeys","volume":"259","author":"Gomez\u2010Mancilla B","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S0317167100041500","article-title":"Levodopa\u2010induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us?","volume":"19","author":"B\u00e9dard PJ","year":"1992","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(86)90131-0"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(84)90467-1"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245479"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090103"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245783"},{"key":"e_1_2_1_16_2","first-page":"115","volume-title":"The basal ganglia","author":"Denny\u2010Brown D","year":"1976"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(76)90213-2"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)39350-X","article-title":"Differential effect of selective D\u20101 and D\u20102 dopamine receptor agonists on levodopa\u2010induced dyskinesia in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010exposed monkeys","volume":"267","author":"Blanchet P","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(90)90110-V"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890100304"},{"key":"e_1_2_1_21_2","series-title":"Advances in neurology","first-page":"113","volume-title":"Parkinson's disease: from basic research to treatment","author":"B\u00e9dard PJ","year":"1993"},{"key":"e_1_2_1_22_2","first-page":"143","article-title":"Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease","volume":"43","author":"Lees AJ","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90783-3"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.6.927"},{"key":"e_1_2_1_25_2","series-title":"Advances in neurology","first-page":"119","volume-title":"Parkinson's disease: from basic research to treatment","author":"Nomoto M","year":"1993"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(92)90125-A"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410310514"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080205"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90508-N"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870070309"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90556-J"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870100606","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870100606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:31:37Z","timestamp":1760959897000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870100606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,11]]}},"alternative-id":["10.1002\/mds.870100606"],"URL":"https:\/\/doi.org\/10.1002\/mds.870100606","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,11]]}}}